Financials data is unavailable for this security.
View more
Year on year Richter Gedeon Vegyeszeti Gyar Nyrt 's net income fell -6.05% from 169.08bn to 158.85bn despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 22.72% to 24.42%.
| Gross margin | 68.64% |
|---|---|
| Net profit margin | 28.40% |
| Operating margin | 26.68% |
| Return on assets | 16.92% |
|---|---|
| Return on equity | 20.75% |
| Return on investment | 19.01% |
More ▼
Cash flow in HUFView more
In 2023, Richter Gedeon Vegyeszeti Gyar Nyrt did not generate a significant amount of cash. However, the company earned 123.67bn from its operations for a Cash Flow Margin of 15.36%. In addition the company used 20.00bn on investing activities and also paid 103.81bn in financing cash flows.
| Cash flow per share | 1,513.73 |
|---|---|
| Price/Cash flow per share | 7.19 |
| Book value per share | 6,425.20 |
|---|---|
| Tangible book value per share | 4,582.33 |
More ▼
Balance sheet in HUFView more
| Current ratio | 3.26 |
|---|---|
| Quick ratio | 2.03 |
| Total debt/total equity | 0.0477 |
|---|---|
| Total debt/total capital | 0.0454 |
More ▼
Growth rates in HUF
Year on year, growth in dividends per share increased 10.39% while earnings per share excluding extraordinary items fell by -5.25%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
| Div yield(5 year avg) | 3.25% |
|---|---|
| Div growth rate (5 year) | 33.94% |
| Payout ratio (TTM) | 34.46% |
| EPS growth(5 years) | 35.28 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 88.43 |
More ▼
